Healthcare News by GLG Council Members

HIV/AIDS DRUG-INDUS BIOTECH

October 27, 2009

Analysis by: GLG Expert Contributor

Analysis of:Indus Biotech develops drug to control HIV/AIDS | www.pharmabiz.com

This is indeed great news for HIV sufferers all over the world. Since the drug is derived from botanical sources, the cost will be within the reach of millions in the developing world. It will also help those infected with HIV in the developed world where the cost of conventional therapies are extremely high.Ashok Bendre

Andrew DahlPresident Ophthalmology Consultants

Lumigan X EU Committee Recomendation

October 27, 2009

Analysis of:EU committee backs marketing approval of Lumigan | www.pharmabiz.com

The Committee for Medicinal Products for Human Use (CHMP) of the European Union has recommended granting a Marketing Authorization for a new version of Allergan's Lumigan (bimatoprost ophthalmic solution). This new version will be marketed as Lumigan-X after approval. Lumigan X offers Allergan a new formulation to compete against generic versions of its glaucoma drug Lumigan after patent protection for Lumigan expires shortly.There will be very limited demand for Lumigan-X.

Turn around signs seen in healthcare !!! Dr. Reddy's & Ranbaxy beat the trend!!!

October 27, 2009

Analysis by: GLG Expert Contributor

Analysis of:UPDATE 1-New generics help India Dr Reddy's beat Q2 f'cast | in.reuters.com

After 4 - 5 quaters of negative growth, cost cuts, product rationalization etc... we have some good news from bell weather stocks of Indian pharma market.Dr. Reddy's & Ranbaxy both are reporting profits after of year of dismal performance.This is also a sign of overall market changing its down ward trajectory.

a natural response by competitor

October 26, 2009

Analysis by: GLG Expert Contributor

Analysis of:Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/Sifrol® prolonged-release, once daily tablet for the treatment of Parkinson`s disease | www.pipelinereview.com

1. Requip XL will be coming out soon so BI had to come up with Mirapex once daily SR.2. Once daily dosing is probably better for our Parkinson's patients as this will provide continuous dopaminergic stimulation with less fluctuation.

Jon StrasserAssistant Professor of Radiation OncologyTHOMAS JEFFERSON UNIVERSITY

Particle Beam Technology - Costly and a limited utility

October 26, 2009

Analysis of:Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov

Over the last several years, there has been an increased interest in the US in particle beam therapy as the costs have come down and large manufacturers have become more efficient in installing these centers. In addition, private companies have made a business model of building proton centers - mostly by treating prostate cancer.Protons are incredibly useful in specific diseases - ie ocular melanoma, pediatric cancers, but are too costly without proven benefit for our health care system.

Pharm awakens to accountability

October 25, 2009

Analysis by: GLG Expert Contributor

Analysis of:Pfizer Subsidiary Hit With Record Fine For Misbranding Bextra | online.wsj.com

Pfizer gets disciplined for mismarketing four steeds in their drug stable. $2.3B.

The Holy Grail of Saving Lives and Saving Money Found to be Achievable--Again!

October 23, 2009

Analysis by: GLG Expert Contributor

Analysis of:Hospital Collaborative Finds Sharing Data Saves Costs, Lives | www.healthleadersmedia.com

As the health care reform march continues to drone on in D.C., we continue to hear naysayers claim that saving money will result in losing lives. Once again, in the results of the most recent study from the Premier health care alliance's national collaborative, QUEST: High Performance Hospitals, the Cassandras have been proven wrong.

Ken PowellPresidentGenesis Business Development, LLC

BD to Acquire Handy Lab

October 23, 2009

Analysis of:BD Announces Agreement to Acquire HandyLab, Inc. | finance.yahoo.com

BD has entered into a definitive agreement to acquire privately held Handy Lab, Inc.  This development will provide BD with the automated, molecular diagnostic platform to compete in the many, high growth molecular diagnostics market segments.

Particle Beam Radiation Therapy (PBRT) life saving technology but who will pay?

October 22, 2009

Analysis by: GLG Expert Contributor

Analysis of:Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov

PBRT is an exciting technology that has emerged as a life saver for children and many adults with head/neck , eye and other difficult to treat cancers. Proton Centers require massive investments from $100-250 million. Payor groups from Medicare to commercial plans are faced with whether to pay for this promising technology and what diagnoses are appropriate. This study looks at the effectiveness of PBRT vs. IMRT and other current treatment options. But can centers have an ROI on uncommon cancer?

Update on tocilizumab treatment for RA

October 22, 2009

Analysis by: GLG Expert Contributor

Analysis of:Data from LITHE study shows RA particularly affects the small joints of the hands and feet | www.pharmabiz.com

Impressive results for tocilizumab treatment of RA.

Previous Page : 12345678910Next51 to 60 of 7849